Sunshine Biopharma (SBFM) EBITDA Margin (2015 - 2026)
Sunshine Biopharma (SBFM) posted EBITDA Margin of 17.25% for Q1 2026, up 17.33% on a QoQ basis from 20.87% in Q4 2025, and down 270.0% year-over-year from 10.15% in Q1 2025.
Sunshine Biopharma (SBFM) EBITDA Margin (2015 - 2026) Analysis & Trends
Sunshine Biopharma's EBITDA Margin history runs 10 years deep, the most recent figure standing at 17.25% for Q1 2026.
- Quarterly EBITDA Margin fell 270.0% year-over-year to 17.25% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 17.83% (down 207.0% YoY) and the FY2025 annual result came in at 17.15%, down 49.0% from the prior year.
- EBITDA Margin was 17.25% for Q1 2026 at Sunshine Biopharma, up from 20.87% in the prior quarter.
- Across five years, EBITDA Margin topped out at 11.54% in Q3 2025 and bottomed at 1293.58% in Q3 2022.
- A 5-year average of 210.77% and a median of 18.23% in 2023 frame the typical range for EBITDA Margin.
- Peak annual rise in EBITDA Margin reached 218701 bps in 2022, while the deepest fall reached 30847 bps in 2022.
- Sunshine Biopharma's EBITDA Margin stood at 593.01% in 2022, then soared by 97 bps to 15.46% in 2023, then sank by 37 bps to 21.24% in 2024, then climbed by 2 bps to 20.87% in 2025, then climbed by 17 bps to 17.25% in 2026.
- Business Quant data shows SBFM's EBITDA Margin at 17.25% in Q1 2026, 20.87% in Q4 2025, and 11.54% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 91.98 Bn | 90.11 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.92 Bn | 32.18 Bn | 1.97 Bn | 16.37% |
| 3 | Zoetis | 32.99 Bn | 31.05 Bn | 1.62 Bn | 36.83% |
| 4 | Takeda Pharmaceutical | 27.75 Bn | 23.69 Bn | 4.39 Bn | -38.02% |
| 5 | United Therapeutics | 23.03 Bn | 20.87 Bn | 648.10 Mn | 41.69% |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - | - |
| 7 | Viatris | 20.51 Bn | 18.70 Bn | 1.16 Bn | -2.27% |
| 8 | Neurocrine Biosciences | 18.10 Bn | 16.78 Bn | 800.70 Mn | 23.74% |
| 9 | Elanco Animal Health | 12.77 Bn | 12.34 Bn | 785.00 Mn | 21.23% |
| 10 | Sunshine Biopharma | 696,643.46 | -6.22 Mn | 2.18 Mn | -17.25% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.25% |
| Dec 31, 2025 | -20.87% |
| Sep 30, 2025 | -11.54% |
| Jun 30, 2025 | -21.83% |
| Mar 31, 2025 | -14.56% |
| Dec 31, 2024 | -21.24% |
| Sep 30, 2024 | -13.12% |
| Jun 30, 2024 | -13.63% |
| Mar 31, 2024 | -17.91% |
| Dec 31, 2023 | -15.46% |
| Sep 30, 2023 | -13.08% |
| Jun 30, 2023 | -18.23% |
| Mar 31, 2023 | -37.37% |
| Dec 31, 2022 | -593.01% |
| Sep 30, 2022 | -1,293.58% |
| Jun 30, 2022 | -462.92% |
| Mar 31, 2022 | -997.48% |
| Dec 31, 2021 | -328.52% |
| Sep 30, 2021 | -985.11% |
| Jun 30, 2021 | -734.95% |